PhaseBio Pharmaceuticals, Inc.

57 articles with PhaseBio Pharmaceuticals, Inc.

• PhaseBio to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

  9/9/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the upcoming H.C. Wainwright 22 nd Annual Global Investment Conference on Tuesday, September 15, at 12:00

• PhaseBio to Present at the William Blair Biotech Focus Conference 2020

  8/3/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), today announced that Chief Executive Officer Jonathan P. Mow and other members of the management team will participate in a fireside chat at the upcoming William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2:00 p.m. EDT.

• 

  Clinical Catch-Up: July 13-17

  7/20/2020

  It was a surprisingly big week for clinical trial updates related to COVID-19, although there was plenty of non-COVID-19 news as well. Here’s a look.

• DSG Supports PhaseBio Pharmaceuticals with Unified Clinical Trial Software Platform for COVID-19 Trial

  7/17/2020

  DSG, Inc. , a global leader of eClinical software solutions and services for the life sciences industry has successfully launched a COVID-19 study with PhaseBio Pharmaceuticals for its potentially pivotal clinical trial evaluating PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS). Understanding the urgent nature

• 

  Biopharma Update on the Novel Coronavirus: July 17

  7/17/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.

• PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

  7/16/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has dosed the first patient in VANGARD, a potentially pivotal Phase 2 clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

• PhaseBio Launches Clinical Trial to Evaluate PB1046 as a Treatment for Hospitalized COVID-19 Patients

  5/27/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

• PhaseBio Reports First Quarter 2020 Financial Results and Recent Business Highlights

  5/12/2020

  PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, reported financial results from the first quarter ending March 31, 2020 and provided an update on corporate activities.

• PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights

  3/30/2020

  PhaseBio today reported financial results for the fourth quarter and full-year ended December 31, 2019, and provided an update on corporate activities.

• PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference

  2/26/2020

  PhaseBio Pharmaceuticals, Inc. announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4, at 10:40 a.m. EST in Boston.

• PhaseBio Appoints Alex C. Sapir to Board of Directors

  2/13/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of Alex C. Sapir to its board of directors.

• PhaseBio Announces European Regulatory Update for PB2452

  2/11/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), today announced that PB2452 has been granted PRIority MEdicines (PRIME) designation by the European Medicines Agency (EMA) for reversal of the antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or requiring urgent surgery or an invasive procedure.

• PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at the 14th Pulmonary Vascular Research Institute World Congress

  2/4/2020

  Data continue to support potential of once-weekly VIP analogue for adults with pulmonary arterial hypertension

• PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

  1/13/2020

  PhaseBio to be responsible for all development, manufacturing and commercialization

• PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

  1/10/2020

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced a financing and co-development collaboration with SFJ Pharmaceuticals to support the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor.

• PhaseBio to Present at Stifel 2019 Healthcare Conference

  11/15/2019

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Stifel 2019 Healthcare Conference

• PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress

  11/14/2019

  Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452

• PhaseBio To Report Third Quarter 2019 Financial Results and Recent Corporate Progress on November 14, 2019

  11/7/2019

  PhaseBio Pharmaceuticals, Inc. announced that on November 14, 2019, before the open of the U.S. financial markets, it will report financial results for the third quarter 2019 and recent corporate progress.

• PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor

  10/15/2019

  PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the first patient has been dosed in a Phase 2b clinical trial of PB2452,

• 

  Clinical Catch-Up: September 23-27

  9/30/2019

  It was a moderately busy week for clinical trial news. Here’s a look.